drugset
drugset / Trial / NCT07253896

Efficacy and Safety of AK104 Combined With Chemotherapy and Cetuximab or Bevacizumab

NCT07253896 ↗

Phase 2 Recruiting 40 enrolled Second Affiliated Hospital, School of Medicine, Zhejiang University
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the objective response rate (ORR) of AK104 combined with chemotherapy and cetuximab or bevacizumab in second-line treatment of MSS type advanced colorectal cancer

Timeline

Start
2024-01-03
Primary completion
2026-01-03
Completion
2027-01-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody — —
Subject Cadonilimab Monoclonal antibody — —
Subject Cetuximab Monoclonal antibody — —

Indications

No indication recorded.